D. Patients, 8%) ont eu une toxicité cardiaque durant le traitement par trastuzumab. Elle était réversible chez 13 d'entre eux (72,2%), vol.5

, Les évènements cardiaques étaient :-un BAV 3 (bloc auriculo-ventriculaire) symptomatique (1 patient)

, Quinze patients (6,5%) ont présenté une toxicité cardiaque pendant la chimiothérapie, vol.18

, Vingt-huit patients (12,1%) ont développé au moins un événement cardiaque

, L'âge compris entre 76 et 80 ans et supérieur à 80 ans avec des HR respectifs à, vol.3

, En analyse multivariée restaient significatifs la présence de comorbidités cardiaques et l'âge. 2. Bibliographie

K. D. Miller, R. L. Siegel, C. C. Lin, A. B. Mariotto, J. L. Kramer et al., Cancer treatment and survivorship statistics, CA Cancer J Clin, vol.66, issue.4, pp.271-89, 2016.

S. Rosso, A. Gondos, R. Zanetti, F. Bray, M. Zakelj et al., Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States, Eur J Cancer. déc, vol.46, issue.18, pp.3351-3358, 2010.

E. H. Romond, E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, vol.353, issue.16, pp.1673-84, 2005.

M. J. Piccart-gebhart, M. Procter, B. Leyland-jones, A. Goldhirsch, M. Untch et al.,

, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, vol.353, issue.16, pp.1659-72, 2005.

D. Slamon, W. Eiermann, N. Robert, T. Pienkowski, M. Martin et al., Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, vol.365, issue.14, pp.1273-83, 2011.

N. Denduluri, M. Chavez-macgregor, M. L. Telli, A. Eisen, S. L. Graff et al.,

, Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update, J Clin Oncol. 22 mai, 2018.

L. Talarico, G. Chen, and R. Pazdur, Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration, J Clin Oncol, vol.22, issue.22, pp.4626-4657, 2004.

I. Vaz-luis, N. U. Lin, N. L. Keating, W. T. Barry, J. Lii et al., Treatment of earlystage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab, Breast Cancer Res Treat, vol.159, issue.1, pp.151-62, 2016.

A. I. Neugut, G. C. Hillyer, L. H. Kushi, L. Lamerato, N. Leoce et al., Noninitiation and early discontinuation of adjuvant trastuzumab in women with localized HER2positive breast cancer. Breast Cancer, vol.21, pp.780-785, 2014.

I. Vaz-luis, N. L. Keating, N. U. Lin, H. Lii, E. P. Winer et al., Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study, J Clin Oncol. 20 mars, vol.32, issue.9, pp.927-961, 2014.

. Jéhannin-ligier-k, Projection de l'incidence et de la mortalité par cancer en France métropolitaine en, 2017.

B. D. Smith, J. Jiang, S. S. Mclaughlin, A. Hurria, G. L. Smith et al., Improvement in breast cancer outcomes over time: are older women missing out?, J Clin Oncol. 10 déc, vol.29, issue.35, pp.4647-53, 2011.

D. A. Berry, K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke et al., Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, vol.353, issue.17, pp.1784-92, 2005.

, Targeting of mammography screening according to life expectancy in women aged 75

S. X. Sun, C. S. Hollenbeak, and A. M. Leung, Deviation from the Standard of Care for Early Breast Cancer in the Elderly: What are the Consequences?, Ann Surg Oncol. août, vol.22, issue.8, pp.2492-2501, 2015.

C. Owusu, D. Buist, T. S. Field, T. L. Lash, S. S. Thwin et al.,

G. H. Lyman, D. C. Dale, and J. Crawford, Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices, J Clin Oncol. 15 déc, vol.21, issue.24, pp.4524-4555, 2003.

J. A. Foster, G. D. Salinas, D. Mansell, J. C. Williamson, and L. L. Casebeer, How does older age influence oncologists' cancer management?, Oncologist, vol.15, issue.6, pp.584-92, 2010.

P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg et al.,

, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol. 10 févr, vol.26, issue.5, pp.778-85, 2008.

L. Duchateau, Preoperative chemotherapy in primary operable breast cancer: results from the

, European Organization for Research and Treatment of Cancer trial 10902, J Clin Oncol, vol.19, issue.22, pp.4224-4261, 2001.

L. Gianni, J. Baselga, W. Eiermann, V. G. Porta, V. Semiglazov et al., Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, ATAC trial, Lancet Oncol. déc, vol.11, issue.12, pp.1135-1176, 2010.

M. M. Regan, P. Neven, A. Giobbie-hurder, A. Goldhirsch, B. Ejlertsen et al.,

, Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up, Lancet Oncol, vol.12, issue.12, pp.1101-1109, 2011.

E. J. Blok, J. R. Kroep, E. Meershoek-klein-kranenbarg, D. Carpentier, M. Putter et al., Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05), J Natl Cancer Inst. 1 janv, vol.110, issue.1, 2018.

M. Colleoni, W. Luo, P. Karlsson, J. Chirgwin, S. Aebi et al., Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol. janv, vol.19, issue.1, pp.127-165, 2018.

P. E. Goss, J. N. Ingle, K. I. Pritchard, N. J. Robert, H. Muss et al.,

, Inhibitor Adjuvant Therapy to 10 Years, N Engl J Med. 21 juill, vol.375, issue.3, pp.209-228, 2016.

H. J. Burstein, S. Temin, H. Anderson, T. A. Buchholz, N. E. Davidson et al.,

, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update, J Clin Oncol. 20 juill, vol.32, issue.21, pp.2255-69, 2014.

N. Howlader, S. F. Altekruse, C. I. Li, V. W. Chen, C. A. Clarke et al., US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status, J Natl Cancer Inst. 28 avr, vol.106, issue.5, 2014.

Y. Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities, Eur J Cancer. sept, vol.37, 2001.

R. A. Freedman, N. L. Keating, N. U. Lin, E. P. Winer, I. Vaz-luis et al., Breast cancer-specific survival by age: Worse outcomes for the oldest patients, Cancer. 15 mai, vol.124, issue.10, pp.2184-91, 2018.

H. S. Earp, T. L. Dawson, X. Li, and H. Yu, Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research, Breast Cancer Res Treat. juill, vol.35, issue.1, pp.115-147, 1995.

Y. Yarden and M. X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol. févr, vol.2, issue.2, pp.127-164, 2001.

F. Penault-llorca, A. Vincent-salomon, G. Macgrogan, P. Roger, I. Treilleux et al., , 2014.

, Ann Pathol. oct, vol.34, issue.5, pp.352-65, 2014.

A. C. Wolff, M. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al.,

, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer

, College of American Pathologists clinical practice guideline update, J Clin Oncol, vol.31, issue.31, pp.3997-4013, 2013.

M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J. Zhou et al., Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens, J Clin Oncol. 15 juill, vol.20, issue.14, pp.3095-105, 2002.

A. Goldhirsch, R. D. Gelber, M. J. Piccart-gebhart, E. De-azambuja, M. Procter et al.,

, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet. 21 sept, vol.382, issue.9897, pp.1021-1029, 2013.

S. Balduzzi, S. Mantarro, V. Guarneri, L. Tagliabue, V. Pistotti et al., Trastuzumabcontaining regimens for metastatic breast cancer, Cochrane Database Syst Rev. 12 juin, issue.6, p.6242, 2014.

X. Pivot, G. Romieu, M. Debled, J. Pierga, P. Kerbrat et al., 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol. juill, vol.14, issue.8, pp.741-749, 2013.

L. Gianni, W. Eiermann, V. Semiglazov, A. Lluch, S. Tjulandin et al.,

, Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2negative cohort, Lancet Oncol. mai, vol.15, issue.6, pp.640-647, 2014.

L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch et al.,

, Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2negative cohort, Lancet. 30 janv, vol.375, issue.9712, pp.377-84, 2010.

L. Gianni, T. Pienkowski, Y. Im, L. Roman, L. Tseng et al., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol. janv, vol.13, issue.1, pp.25-32, 2012.

J. Baselga, J. Cortés, S. Kim, S. Im, R. Hegg et al., Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med. 12 janv, vol.366, issue.2, pp.109-128, 2012.

H. Wildiers, B. Van-calster, L. V. Van-de-poll-franse, W. Hendrickx, J. Røislien et al., Relationship between age and axillary lymph node involvement in women with breast cancer, J Clin Oncol. 20 juin, vol.27, issue.18, pp.2931-2938, 2009.

S. G. Diab, R. M. Elledge, and G. M. Clark, Tumor characteristics and clinical outcome of elderly women with breast cancer, J Natl Cancer Inst. 5 avr, vol.92, issue.7, pp.550-556, 2000.

R. Gennari, G. Curigliano, N. Rotmensz, C. Robertson, M. Colleoni et al., Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients, Cancer. 15 sept, vol.101, issue.6, pp.1302-1312, 2004.

M. A. Schonberg, E. R. Marcantonio, D. Li, R. A. Silliman, L. Ngo et al., Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival, J Clin Oncol. 20 avr, vol.28, issue.12, pp.2038-2083, 2010.

A. Molino, M. Giovannini, A. Auriemma, E. Fiorio, A. Mercanti et al.,

. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer, Crit Rev Oncol Hematol. sept, vol.59, issue.3, pp.226-259, 2006.

E. M. De-kruijf, E. Bastiaannet, F. Rubertá, A. De-craen, P. Kuppen et al.,

, Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients, Mol Oncol. juill, vol.8, issue.5, pp.1014-1039, 2014.

E. O. Jenkins, A. M. Deal, C. K. Anders, A. Prat, C. M. Perou et al., Age-specific changes in intrinsic breast cancer subtypes: a focus on older women, Oncologist. oct, vol.19, issue.10, pp.1076-83, 2014.

H. S. Laird-fick, J. C. Gardiner, H. Tokala, P. Patel, S. Wei et al., HER2 status in elderly women with breast cancer, J Geriatr Oncol, vol.4, issue.4, pp.362-369, 2013.

L. De-munck, M. Schaapveld, S. Siesling, J. Wesseling, A. C. Voogd et al.,

, Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands, Breast Cancer Res Treat. août, vol.129, issue.1, pp.229-262, 2011.

E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas, Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort, J Clin Oncol. 20 juin, vol.24, issue.18, pp.2757-64, 2006.

L. A. Smith, V. R. Cornelius, C. J. Plummer, G. Levitt, M. Verrill et al., Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials, BMC Cancer. 29 juin, vol.10, p.337, 2010.

D. A. Patt, Z. Duan, S. Fang, G. N. Hortobagyi, and S. H. Giordano, Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk, J Clin Oncol. 1 sept, vol.25, issue.25, pp.3871-3877, 2007.

C. H. Barcenas, J. Niu, N. Zhang, Y. Zhang, T. A. Buchholz et al., Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer, J Clin Oncol. 1 juill, vol.32, pp.2010-2017, 2014.

H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson et al., Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience, J Clin Oncol. 20 août, vol.25, issue.24, pp.3699-704, 2007.

C. Kenis, L. Decoster, J. Bastin, H. Bode, K. Van-puyvelde et al., Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study, J Geriatr Oncol. mai, vol.8, issue.3, pp.196-205, 2017.

S. H. Giordano, Z. Duan, Y. Kuo, G. N. Hortobagyi, and J. S. Goodwin, Use and outcomes of adjuvant chemotherapy in older women with breast cancer, J Clin Oncol. 20 juin, vol.24, issue.18, pp.2750-2756, 2006.

N. Siegelmann-danieli, V. Khandelwal, G. C. Wood, R. Mainali, J. Prichard et al.,

, Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach, Clin Breast Cancer. avr, vol.7, issue.1, pp.59-66, 2006.

G. H. Lyman, D. C. Dale, and J. Crawford, Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices, J Clin Oncol. 15 déc, vol.21, issue.24, pp.4524-4555, 2003.

T. L. Lash, R. A. Silliman, E. Guadagnoli, and V. Mor, The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer, vol.89, pp.1739-1786, 2000.

C. Bouchardy, E. Rapiti, S. Blagojevic, A. Vlastos, and G. Vlastos, Older female cancer patients: importance, causes, and consequences of undertreatment, J Clin Oncol. 10 mai, vol.25, issue.14, pp.1858-69, 2007.

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score, Cancer. 1 juill, vol.118, issue.13, pp.3377-86, 2012.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al., Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol. 1 sept, vol.29, issue.25, pp.3457-65, 2011.

A. Hurria, M. Naylor, and H. J. Cohen, Improving the quality of cancer care in an aging population: recommendations from an IOM report, JAMA, vol.310, issue.17, pp.1795-1801, 2013.

L. Balducci, Geriatric oncology: challenges for the new century, Eur J Cancer. sept, vol.36, issue.14, pp.1741-54, 2000.

A. G. Pallis, C. Fortpied, U. Wedding, M. C. Van-nes, B. Penninckx et al., EORTC elderly task force position paper: approach to the older cancer patient, Eur J Cancer. juin, vol.46, issue.9, pp.1502-1515, 2010.

C. Bouchardy, E. Rapiti, S. Blagojevic, A. Vlastos, and G. Vlastos, Older female cancer patients: importance, causes, and consequences of undertreatment, J Clin Oncol. 10 mai, vol.25, issue.14, pp.1858-69, 2007.

A. Ali, D. Greenberg, G. C. Wishart, and P. Pharoah, Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England, Br J Cancer. 15 févr, vol.104, issue.4, pp.564-70, 2011.

A. Hurria, S. Mohile, A. Gajra, H. Klepin, H. Muss et al.,

, Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer, J Clin Oncol. 10 juill, vol.34, issue.20, pp.2366-71, 2016.

A. Hurria, S. Gupta, M. Zauderer, E. L. Zuckerman, H. J. Cohen et al., Developing a cancer-specific geriatric assessment: a feasibility study, Cancer, vol.104, issue.9, pp.1998-2005, 2005.

P. Soubeyran, M. Fonck, C. Blanc-bisson, J. Blanc, J. Ceccaldi et al., Predictors of early death risk in older patients treated with first-line chemotherapy for cancer, J Clin Oncol, vol.30, issue.15, pp.1829-1863, 2012.

K. M. Clough-gorr, S. S. Thwin, A. E. Stuck, and R. A. Silliman, Examining five-and ten-year survival in older women with breast cancer using cancer-specific geriatric assessment, Eur J Cancer. avr, vol.48, issue.6, pp.805-817, 2012.

Y. Guigoz, B. Vellas, and P. J. Garry, Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation, Nutr Rev. janv, vol.54, issue.1, pp.59-65, 1996.

M. F. Folstein, S. E. Folstein, and P. R. Mchugh, « Mini-mental state ». A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, vol.12, issue.3, pp.189-98, 1975.

H. Wildiers, M. Mauer, A. Pallis, A. Hurria, S. G. Mohile et al., End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer-Alliance for Clinical Trials in Oncology-International Society Of Geriatric Oncology position article, J Clin Oncol, vol.31, issue.29, pp.3711-3719, 2013.

R. A. Freedman, J. C. Foster, D. K. Seisler, J. M. Lafky, H. B. Muss et al., Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol, 151527.

, J Clin Oncol. févr, vol.35, issue.4, pp.421-452, 2017.

N. E. Avis, K. W. Smith, C. L. Link, G. N. Hortobagyi, and E. Rivera, Factors associated with participation in breast cancer treatment clinical trials, J Clin Oncol. 20 avr, vol.24, issue.12, pp.1860-1867, 2006.
DOI : 10.1200/jco.2005.03.8976

J. S. Mandelblatt, V. B. Sheppard, A. Hurria, G. Kimmick, C. Isaacs et al., Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians, J Clin Oncol. 1 juill, vol.28, pp.3146-53, 2010.

I. Vaz-luis, N. L. Keating, N. U. Lin, H. Lii, E. P. Winer et al., Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study, J Clin Oncol. 20 mars, vol.32, issue.9, pp.927-961, 2014.

J. J. Griggs, S. T. Hawley, J. J. Graff, A. S. Hamilton, R. Jagsi et al., Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample, J Clin Oncol. 1 sept, vol.30, issue.25, pp.3058-64, 2012.

R. A. Freedman, I. Vaz-luis, W. T. Barry, H. Lii, N. U. Lin et al., Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy, Breast Cancer Res Treat. juin, vol.145, issue.2, pp.491-501, 2014.

R. A. Freedman, M. E. Hughes, R. A. Ottesen, J. C. Weeks, Y. He et al., Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network, Cancer. 15 févr, vol.119, issue.4, pp.839-885, 2013.

P. Dall, G. Lenzen, T. Göhler, C. Lerchenmüller, G. Feisel-schwickardi et al.,

, Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany, J Geriatr Oncol, vol.6, issue.6, pp.462-471, 2015.

J. Brollo, G. Curigliano, D. Disalvatore, B. F. Marrone, C. Criscitiello et al.,

, Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials, Cancer Treat Rev. févr, vol.39, issue.1, pp.44-50, 2013.

K. E. Reeder-hayes, A. M. Meyer, S. P. Hinton, K. Meng, L. A. Carey et al., Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer, J Clin Oncol, vol.35, issue.29, pp.3298-305, 2017.

L. Moja, L. Tagliabue, S. Balduzzi, E. Parmelli, V. Pistotti et al., Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev, p.6243, 2012.
DOI : 10.1002/14651858.cd006243

V. Guarneri, D. J. Lenihan, V. Valero, J. Durand, K. Broglio et al., Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience, J Clin Oncol. 1 sept, vol.24, issue.25, pp.4107-4122, 2006.

E. A. Perez, V. J. Suman, N. E. Davidson, G. W. Sledge, P. A. Kaufman et al., Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

, J Clin Oncol. 10 mars, vol.26, issue.8, pp.1231-1239, 2008.

Z. Jawa, R. M. Perez, L. Garlie, M. Singh, R. Qamar et al., Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore), vol.95, p.5195, 2016.

C. Guenancia, A. Lefebvre, D. Cardinale, A. F. Yu, S. Ladoire et al., Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis, J Clin Oncol. 10 sept, vol.34, issue.26, pp.3157-65, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01413012

Y. Hamirani, I. Fanous, C. M. Kramer, A. Wong, M. Salerno et al., Anthracycline-and trastuzumab-induced cardiotoxicity: a retrospective study, Med Oncol. juill, vol.33, issue.7, p.82, 2016.

M. Gunaldi, B. B. Duman, C. U. Afsar, S. Paydas, M. Erkisi et al., Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational singlecentre study, J Oncol Pharm Pract. avr, vol.22, issue.2, pp.242-249, 2016.

G. Curigliano, D. Cardinale, T. Suter, G. Plataniotis, E. De-azambuja et al., Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines, Ann Oncol, vol.23, issue.7, pp.155-166, 2012.

M. Chavez-macgregor, N. Zhang, T. A. Buchholz, Y. Zhang, J. Niu et al.,

, Trastuzumab-related cardiotoxicity among older patients with breast cancer, J Clin Oncol, vol.31, issue.33, pp.4222-4230, 2013.

M. Chavez-macgregor, J. Niu, N. Zhang, L. S. Elting, B. D. Smith et al., Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer, J Clin Oncol. 1 juill, vol.33, pp.2176-83, 2015.

L. Tarantini, S. Gori, P. Faggiano, G. Pulignano, E. Simoncini et al., Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis, Annals of Oncology. 1 déc, vol.23, issue.12, pp.3058-63, 2012.

M. Charlson, T. P. Szatrowski, J. Peterson, and J. Gold, Validation of a combined comorbidity index, J Clin Epidemiol, vol.47, issue.11, pp.1245-51, 1994.

E. De-azambuja, M. J. Procter, D. J. Van-veldhuisen, D. Agbor-tarh, and O. Metzger-filho,

J. Steinseifer, Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01), J Clin Oncol. 10 juill, vol.32, issue.20, pp.2159-65, 2014.

E. Colzani, A. Liljegren, A. Johansson, J. Adolfsson, H. Hellborg et al., Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics, J Clin Oncol, vol.29, issue.30, pp.4014-4035, 2011.

T. Chen, T. Xu, Y. Li, C. Liang, J. Chen et al., Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis, Cancer Treat Rev. juin, vol.37, issue.4, pp.312-332, 2011.

S. H. Giordano, S. Temin, J. J. Kirshner, S. Chandarlapaty, J. R. Crews et al.,

, Systemic therapy for patients with advanced human epidermal growth factor receptor 2positive breast cancer: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol. 1 juill, vol.32, pp.2078-99, 2014.

C. Bouchardy, E. Rapiti, G. Fioretta, P. Laissue, I. Neyroud-caspar et al.,

, Undertreatment strongly decreases prognosis of breast cancer in elderly women, J Clin Oncol, vol.21, pp.3580-3587, 2003.

L. Biganzoli, H. Wildiers, C. Oakman, L. Marotti, S. Loibl et al., Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

, Lancet Oncol. avr, vol.13, issue.4, pp.148-160, 2012.